RE:RE:RE:RE:RE:RE:Wake Up Investment WorldYeah, this is really weird.
The aquisition diversifies the company considerably. They've closed the debt and equity for this deal, with the equity all at prices considerably higher than now. They should have over $600million in EBITDA next year, even without any drug price increases. I'm guessing the pace of acquisitions will slow down for them while they digest this given the market sentiment around their last acquisition and pharma in general. They'll probably focus on paying down debt.
Granted, the share price was probably a little inflated before the deal... but now it seems very cheap.
Am I missing something? I bought shares yesterday.